Glauser TA, Pippenger CE. 2000. Controversies in
blood-level monitoring: reexamining its role in the
treatment of epilepsy.Epilepsia 41 (suppl 8): S6–S15.
Jones AL, Dargan PI. 2001.Churchill’s Pocketbook of
Toxicology. Churchill Livingstone: London; 69–76
and pp. 80–84 (ISBN 0-4430-6476-8).
Lange R, Dietrich D. 2002. Environmental risk assess-
ment of pharmaceutical drug substances-conceptual
considerations.Toxicol. Lett. 131 :97–104.
Mimaki T. 1998. Clinical pharmacology and therapeu-
tic drug monitoring of zonisamide. Ther. Drug
Monit. 20 : 593–597.
Nowak G. 2001. Clinical monitoring of hirudin and
direct thrombin inhibitors.Semin. Thromb. Hemos-
tas. 27 : 537–541.
Ohnishi A, Kato M, Kojima J, Ushiama H, Yoneko M,
Kawai H. 2003. Differential pharmacokinetics of
theophylline in elderly patients.Drugs Aging 20 :
71–84.
Reynolds DJ, Aronson JK. 1993. ABC of monitoring
drug therapy. Making the most of plasma drug
concentration measurements. Br. Med. J. 306 :
48–51.
Sproule BA, Naranjo CA, Brenmer KE, Hassan PC.- Selective serotonin reuptake inhibitors and
CNS drug interactions. A critical review of the
evidence.Clin. Pharmacokinet. 33 : 454–471.
Ursolak PJ. 1989. Therapeutic monitoring of anti-
depressant drugs: guidelines updated.Ther. Drug
Monit. 11 : 497–507.
380 CH28 MONITORING DRUG CONCENTRATIONS IN CLINICAL PRACTICE